On 19-20 July in Italy, Celularity will present data on the potential therapeutic application of decellularised flowable placental connective tissue matrix (DF-CTM) for tendon repair at the International Conference on Orthopaedics.

The company hypothesised that the lack of blood and cells in tendon tissue slows down its healing process. The DF-CTM would provide the structural and biochemical matrix components to help tendon healing and reduce inflammation.

Tendon repair usually requires surgery, which can cost an average of $6,000 in the US and take 12 weeks to fully heal.

Titled “A Decellularised Flowable Placental Connective Tissue Matrix Supports Cellular Functions of Human Tenocytes In Vitro,” the presentation will summarise the early DF-CTM data.

The in vitro study showed higher tenocyte proliferation and migration in DF-CTM cultures compared to the control.

The DF-CTM cultures showed diminished response to pro-inflammatory markers, including TNF-α, an inflammatory cytokine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Celularity CEO Robert J Hariri said: “We are very encouraged by the performance of our advanced placental-derived biomaterials, and we believe these data enhance our understanding of the potential application of DF-CTM for tendon repair, which could address a significant unmet need for patients with tendon injuries.

“These early tenocyte data are an important demonstration of our ongoing commitment and focus on innovation leveraging the placental platform we have pioneered.”

According to Celularity’s evaluations, tenocyte proliferation, maintenance of tenocyte phenotype, and attenuated inflammatory response signify a favourable interaction of DF-CTM with human tenocytes.

The US Food and Drug Administration (FDA) in April 2023 approved the first allogeneic stem cell therapy for the treatment of blood cancer.

The company’s immuno-modulatory placenta-derived allogeneic stem cell therapy (IMPACT) candidate, CYNK-101 is being investigated for multiple cancer indications, including lymphoma and gastric carcinomas.